Single DMT Dose Shows Rapid, Lasting Antidepressant Effects in Treatment-Resistant Depression Trial

A single intravenous dose of the psychedelic drug dimethyltryptamine (DMT查看药品详情) combined with psychotherapy produced rapid and sustained antidepressant effects in patients with treatment-resistant depression, according to results from a phase IIa clinical trial published in Nature Medicine.

The randomized, double-blind, placebo-controlled study involved 34 participants with moderate to severe treatment-resistant depression. Half received a single 21.5mg dose of DMT查看药品详情 infused intravenously over 10 minutes, while the other half received a placebo. All participants underwent psychotherapy and follow-up assessments.

Sustained Clinical Benefits

Patients who received DMT查看药品详情 showed significant improvement compared to the placebo group, as measured by scores on a standard depression questionnaire. The antidepressant effects were observed from the first week and lasted from three to six months in some patients.

"There is an immediate antidepressant effect that is significantly sustained over a three-month period and that's exciting because this is one session with a drug, embedded in psychological support," said Dr. David Erritzoe, a psychiatrist at Imperial College London查看公司主页 and lead investigator on the trial.

The study targeted patients with treatment-resistant depression, defined as major depressive disorder that has not responded to at least two antidepressants. An estimated 100 million people worldwide have this condition, with about half unable to perform routine daily tasks.

Practical Advantages Over Other Psychedelics

DMT查看药品详情, an active ingredient of the ayahuasca brew used in South American shamanistic rituals, induces powerful hallucinogenic experiences that can alter people's sense of time and space. However, its effects are notably shorter than other psychedelics being studied for depression.

At the doses used in trials, DMT查看药品详情 induces a more intense but shorter trip than psilocybin, with the experience lasting about 25 minutes compared with a couple of hours for psilocybin. This shorter duration could make DMT-assisted therapy easier for clinics to deliver, though patients may need more support to recover from particularly intense DMT trips.

The brief nature of the intervention - a 10-minute infusion with acute psychedelic effects lasting around 30 minutes - greatly facilitates large-scale implementation compared to other psychedelic interventions that require patients to remain under observation for up to eight hours.

Study Design and Limitations

In the second stage of the trial, all participants received a dose of DMT查看药品详情 with therapy. Researchers found no additional benefit in those who had two doses in total, suggesting a single dose may suffice. The trial was designed, funded and sponsored by Cybin UK (搜索)搜索该词条, a neuropsychiatric firm.

However, the study has important limitations. The sample size was small with only 17 patients per arm, and the open-label design only allowed efficacy evaluation against placebo for two weeks, as all patients received a second dose after this period. While subsequent improvement was maintained for up to three months, it's not possible to determine the contribution of placebo effects or other contextual factors.

Mechanism and Future Implications

Psychedelics are thought to enhance psychotherapy effects by helping people break entrenched and unhelpful thinking patterns. Erritzoe likens the effect to shaking up snow on a mountain and flattening hills and valleys so people can easily find new routes.

The study follows positive trials with psilocybin, the active ingredient in magic mushrooms, which has raised hopes for regulatory approval for depression treatment. If regulators approve psychedelics for treating depression in the UK, researchers expect them to become available only through private clinics initially.

DMT查看药品详情 remains in early stages of clinical development for mental disorders, with phase II trials evaluating preliminary efficacy and safety in relatively small samples. Large-scale phase III trials are not yet available to support regulatory approval, placing it behind psilocybin, which already has advanced phase III programs for major depression.